<DOC>
	<DOCNO>NCT01968239</DOCNO>
	<brief_summary>The aim trial evaluate efficacy safety intravitreal injection ranibizumab treatment macular edema due BRVO re-treatment regimen guide morphological macular change detect OCT compare re-treatment accord SmPC define re-treatment criterion ( case increase CRT concomitant decrease BCVA ) .</brief_summary>
	<brief_title>Proof Concept Study Re-treatment BRVO With Ranibizumab Guided OCT</brief_title>
	<detailed_description>In prospective , randomize , interventional , controlled phase IIb clinical functional result treatment ranibizumab patient macular edema due branch retinal vein occlusion give accord morphological change detect OCT compare standard re-treatment criterion accord SmPC</detailed_description>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Recurrence macular edema define kind fluid accumulation macula ( microcystic change without increase central retinal thickness ) detect OCT month 1 6 last Lucentis injection without decrease BCVA measure ETDRS chart 2 . Diagnosis BRVO macular edema treat least three intravitreally applied injection ranibizumab upload phase treatment 3 . Age â‰¥ 18 year 4 . Ability willingness attend schedule visit assessment 5 . For sexually active woman childbearing potential , use appropriate form contraception ( abstinence ) duration study 1 . Macular edema due another etiology retinal vein occlusion ( e.g . diabetic maculopathy , uveitis , age relate macular degeneration , IrvineGass syndrome ) 2 . Evidence upon examination vitreoretinal interface disease ( e.g. , vitreomacular traction , epiretinal membrane ) , either clinical examination OCT , think contribute macular edema 3 . Use intraocular periocular injection steroid study eye ( e.g. , triamcinolone ) prior study entry 4 . History cerebral vascular accident , myocardial infarction , transient ischemic attack last 6 month 5 . Pregnancy ( positive pregnancy test ) lactation 6 . History allergy humanize antibody component ranibizumab formulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>BRVO</keyword>
	<keyword>Macular edema</keyword>
	<keyword>Ranibizumab</keyword>
	<keyword>re-treatment</keyword>
</DOC>